Tag: Proteasome inhibitor

Tag Visualization: Top 50 related tags by occurrence

Recent Related Articles to Proteasome inhibitor

US Multiple Myeloma Drugs Market to witness massive growth | 2020-2028

Added to Collection on: 2021-07-05 16:52:30

Tags for this article:

Drugs
Clinical medicine
Health
Orphan drugs
Breakthrough therapy
Cancer treatments
Daratumumab
Multiple myeloma
Elotuzumab
Bortezomib
Proteasome inhibitor
Monoclonal antibody

Click the tags to see associated articles and topics

View Article Details
Panobinostat From Bench to Bedside: Rethinking the Treatment Paradigm for Multiple Myeloma

Added to Collection on: 2021-08-03 19:31:36

Tags for this article:

Orphan drugs
Drugs
Clinical medicine
Medicine
Cancer treatments
Antineoplastic drugs
Indoles
Panobinostat
Multiple myeloma
Histone deacetylase inhibitor
Proteasome inhibitor

Click the tags to see associated articles and topics

View Article Details
Current and Emerging Therapies for Relapsed and Refractory Multiple Myeloma

Added to Collection on: 2021-08-11 12:56:15

Tags for this article:

Drugs
Orphan drugs
Health care
Clinical medicine
Multiple myeloma
Lenalidomide
Daratumumab
Pomalidomide
Belantamab mafodotin
Proteasome inhibitor
Melphalan flufenamide
Relapse
the translational genomics research institute
Hans C. Lee
the university of texas md anderson cancer center

Click the tags to see associated articles and topics

View Article Details
Active Biotech: Tasquinimod clinical development in multiple myeloma advances into ...

Added to Collection on: 2021-10-03 19:30:00

Tags for this article:

Drugs
Orphan drugs
Health care
Clinical medicine
Multiple myeloma
Ixazomib
Lenalidomide
Immunomodulatory imide drug
Proteasome inhibitor
Daratumumab
Isatuximab
Active Biotech AB
tasquinimod
Active Biotech AB (publ)
STOCKHOLM

Click the tags to see associated articles and topics

View Article Details
FDA Approves Janssen, Legend Biotech's CAR T-Cell Therapy Carvykti for Multiple Myeloma

Added to Collection on: 2022-03-01 20:47:07

Tags for this article:

Health sciences
Clinical medicine
Medicine
Orphan drugs
Breakthrough therapy
Protein domains
Gene therapy
T cells
B-cell maturation antigen
Chimeric antigen receptor T cell
Multiple myeloma
Proteasome inhibitor
legend biotech
Janssen Pharmaceuticals

Click the tags to see associated articles and topics

View Article Details
Global Multiple Myeloma Drugs Market 2022 to 2028 Analysis by Top Key players ... - Energy Siren

Added to Collection on: 2022-04-02 19:19:26

Tags for this article:

Articles
Health sciences
Business process
Business
Market structure
Marketing strategy
Multiple myeloma
Market analysis
Market research
Proteasome inhibitor
Pharmaceutical industry
Market

Click the tags to see associated articles and topics

View Article Details
U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager ...

Added to Collection on: 2022-10-26 08:36:02

Tags for this article:

Medicine
Drugs
Clinical medicine
Orphan drugs
Monoclonal antibodies
Multiple myeloma
RTT
Takeda Pharmaceutical Company
Plasma cell dyscrasias
Proteasome inhibitor
Daratumumab
Bortezomib
Johnson & Johnson
U.S. FDA
u.s. food and drug administration
janssen pharmaceutical

Click the tags to see associated articles and topics

View Article Details
FDA Requests Belantamab Mafodotin for R/R Multiple Myeloma Be Pulled From US Market

Added to Collection on: 2022-11-22 23:02:40

Tags for this article:

Drugs
Orphan drugs
Medicine
Clinical medicine
Daratumumab
Bortezomib
Pomalidomide
Multiple myeloma
Proteasome inhibitor
Dexamethasone
Isatuximab
Carfilzomib

Click the tags to see associated articles and topics

View Article Details
Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in ...

Added to Collection on: 2024-05-24 20:08:17

Tags for this article:

Orphan drugs
Multiple myeloma
Talquetamab
Idecabtagene vicleucel
Teclistamab
CAR T cell
Ciltacabtagene autoleucel
Lenalidomide
Bispecific monoclonal antibody
Proteasome inhibitor
Monoclonal antibody
B-cell maturation antigen

Click the tags to see associated articles and topics

View Article Details
Belantamab Mafodotin–Based PFS Benefits in Difficult-to-Treat R/R Myeloma Subgroups

Added to Collection on: 2024-07-01 13:06:37

Tags for this article:

Orphan drugs
Multiple myeloma
Belantamab mafodotin
Daratumumab
Bortezomib
Antibody-drug conjugate
Lenalidomide
Monomethyl auristatin F
Proteasome inhibitor
Dexamethasone
Cereblon E3 ligase modulator
B-cell maturation antigen

Click the tags to see associated articles and topics

View Article Details